DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Netupitant is an investigational drug.
There have been 12 clinical trials for Netupitant. The most recent clinical trial was a Phase 3 trial, which was initiated on November 25th 2016.
The most common disease conditions in clinical trials are Vomiting, Nausea, and Neoplasms. The leading clinical trial sponsors are Helsinn Healthcare SA, Consorzio Oncotech, and PSI CRO AG.
There are twenty-eight US patents protecting this investigational drug and three hundred and ninety-six international patents.
Recent Clinical Trials for Netupitant
|Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin||Helsinn Healthcare SA||Phase 2/Phase 3|
|Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin||Christina Ruhlmann||Phase 2/Phase 3|
|A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cance||George Clinical Pty Ltd||Phase 3|
Top disease conditions for Netupitant
Top clinical trial sponsors for Netupitant
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Netupitant||Start Trial||Crystalline forms of fosnetupitant||Helsinn Healthcare SA (Lugano/Pazzallo, CH)||Start Trial|
|Netupitant||Start Trial||Brain, spinal, and nerve injury treatment||EUSTRALIS PHARMACEUTICALS LIMITED (Melbourne, Victoria, AU)||Start Trial|
|Netupitant||Start Trial||Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-to- lyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnet- upitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator||Helsinn Healthcare SA (Lugano/Pazzallo, CH)||Start Trial|
|Netupitant||Start Trial||Crystalline forms of an NK-1 antagonist||Helsinn Healthcare SA (Pazzallo-Lugano, CH)||Start Trial|
|Netupitant||Start Trial||Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system||Chase Pharmaceuticals Corporation (Washington, DC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Netupitant||European Patent Office||3359547||2035-10-06||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|